CytoSorbents, Inc.
7 Deer Park Drive
Suite K
Monmouth Junction
New Jersey
08852
United States
Tel: 732-329-8885
Fax: 732-329-8650
Website: http://www.cytosorbents.com/
Email: info@cytosorbents.com
About CytoSorbents, Inc.
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is CE Mark certified and is currently distributed in 37 countries around the world as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy.YEAR FOUNDED:
February 2012
LEADERSHIP:
Founders: Christian Steiner and Phillip Chan
CEO: Phillip Chan
JOBS:
Please click here for CytoSorbents job opportunities.
FOLLOW CYTOSORBENTS:
Tweets by CytoSorbents
407 articles about CytoSorbents, Inc.
-
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
3/6/2024
CytoSorbents Corporation, a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2023 financial results on Thursday, March 14th, 2024 at 4:30PM EDT.
-
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
2/8/2024
CytoSorbents Corporation announces that Dr. Phillip Chan, Chief Executive Officer, will present at the TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place, in Boston, MA on Wednesday, March 6th, 2024.
-
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
1/17/2024
CytoSorbents Corporation reports on excellent outcomes from a groundbreaking randomized controlled trial using CytoSorb® blood purification during heart transplant, recently published in the European Society of Cardiology journal, ESC Heart Failure.
-
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
12/28/2023
CytoSorbents Corporation announces an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board analysis for the pivotal U.S. and Canadian STAR-T randomized controlled trial.
-
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
12/13/2023
CytoSorbents Corporation today announces the closing of its previously announced registered direct offering for the sale by the Company directly to investors of an aggregate of 7,733,090 shares of registered common stock.
-
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
11/9/2023
CytoSorbents Corporation, a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, reported unaudited financial and operating results for the quarter ended September 30, 2023.
-
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
9/19/2023
CytoSorbents Corporation, a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the re-appointment of Kathleen P. Bloch as full-time Chief Financial Officer, effective retroactively to September 2, 2023.
-
CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial
8/14/2023
CytoSorbents Corporation announced that it has completed the pivotal STAR-T randomized, controlled trial, following the last scheduled patient follow-up.
-
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
8/1/2023
CytoSorbents Corporation reported unaudited financial and operating results for the quarter ended June 30, 2023.
-
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
7/26/2023
CytoSorbents Corporation will report second quarter 2023 operating and financial results after the market close on Tuesday, August 1st, 2023.
-
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
7/19/2023
CytoSorbents Corporation announced the appointment of Alexander D’Amico as Chief Financial Officer, to begin employment on August 7, 2023.
-
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
7/7/2023
CytoSorbents Corporation announced that it has completed enrollment of the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor ( STAR-T ) randomized, controlled trial, evaluating the ability of DrugSorb ® -ATR to reduce perioperative bleeding in patients undergoing cardiothoracic surgery on ticagrelor.
-
CytoSorbents Reports First Quarter 2023 Results
5/2/2023
CytoSorbents Corporation, a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, reported unaudited financial and operating results for the quarter ended March 31, 2023.
-
CytoSorbents to Report First Quarter 2023 Operating and Financial Results
4/26/2023
CytoSorbents Corporation will report first quarter 2023 operating and financial results after the market close on Tuesday, May 2, 2023.
-
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
4/20/2023
CytoSorbents Corporation announces that its pivotal STAR-T randomized, controlled trial has enrolled 80 patients, achieving the second of three key enrollment milestones, and triggering a pre-specified Data and Safety Monitoring Board (DSMB) safety review.
-
CytoSorbents Announces Board Chairman Al W. Kraus To Retire
4/19/2023
CytoSorbents Corporation announced today that its Chairman of the Board, Al W. Kraus, will retire at the end of his term in early June 2023.
-
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
3/22/2023
CytoSorbents Corporation announced its scientific program for the 42nd International Symposium on Intensive Care & Emergency Medicine ( ISICEM 2023) Congress being held this week in Brussels, Belgium.
-
CytoSorbents Comments on Bank Exposure and Diversified Cash Position
3/14/2023
CytoSorbents Corporation announced that it does not have any direct financial exposure to Silicon Valley Bank or Signature Bank.
-
CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
3/9/2023
CytoSorbents Corporation today reported financial and operating results for the quarter and year ended December 31, 2022 and provides its 2023 outlook.
-
New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time
3/7/2023
CytoSorbents Corporation announces that hemoadsorption of antithrombotic drugs in cardiothoracic surgery has made its way into the new “2022 Guidelines for the Management of Severe Perioperative Bleeding” by the European Society of Anaesthesiology and Intensive Care and was published in the European Journal of Anaesthesiology last week.